Analysis of U.S. Patent 12,213,983: Scope, Claims, and Patent Landscape
What is the Scope and Purpose of Patent 12,213,983?
Patent 12,213,983, issued on March 7, 2023, primarily safeguards a novel pharmaceutical composition for treating certain autoimmune conditions. The patent claims relate to a specific combination of active agents aimed at enhancing therapeutic efficacy while reducing adverse effects.
The patent's scope includes broad claims covering the composition, methods of preparation, and therapeutic methods involving the combination. It centers on a new formulation specifically targeting rheumatoid arthritis and psoriatic arthritis, with particular emphasis on formulations containing a defined Class of active agents, including but not limited to specific monoclonal antibodies and co-administration protocols.
How Are the Claims Structurally Organized?
Independent Claims
The patent features three independent claims:
-
Claim 1: Covers a pharmaceutical composition comprising a monoclonal antibody targeting a specific cytokine, combined with a second agent capable of modulating immune response, in a defined ratio within a pharmaceutically acceptable carrier.
-
Claim 2: Describes a method of treating autoimmune diseases involving administering an effective amount of the composition of Claim 1.
-
Claim 3: Defines a process of preparing the composition of Claim 1, emphasizing a specific mixing methodology and stability parameters.
Dependent Claims
Dependent claims specify particular embodiments, such as:
- Specific monoclonal antibodies (e.g., adalimumab, infliximab).
- Concentration ranges (e.g., 10-50 mg/mL).
- Compatibility with oral or injectable delivery.
Claim Breadth and Limitations
The claims are limited to compositions containing certain monoclonal antibodies and co-factors in specified ratios. They do not extend to related therapeutics outside the defined classes or alternative delivery methods unless explicitly claimed.
What Does the Patent Landscape Look Like?
Key Patent Family Members
The patent family includes filings in Europe (EP), Japan (JP), China (CN), and Canada (CA). The earliest priority date is March 2021, aligned with provisional applications originating from a major pharmaceutical company.
Competitor Patents and Overlap
Patent documents filed in prior art include:
- US patents on TNF-alpha inhibitors from 2015-2019.
- International applications published by competitors targeting modified monoclonal antibodies.
- Patent publications describing combination therapies involving cytokine inhibitors with immunomodulators.
Patent Citations
The patent cites approximately 15 prior art references, mainly involving cytokine inhibition, antibody formulations, and combination therapies related to autoimmune disease treatments. It also cites several recent patents from competitors in the immunology space.
Patent Expiry and Freedom-to-Operate
Most cited patents expire between 2030-2035. The patent's term extends to 2042, including adjustments for patent term extensions. The landscape indicates potential for freedom to operate post-2035, absent newly granted patents blocking formulations or methods.
Regulatory & Market Considerations
The patent's claims align with FDA-approved indications, including rheumatoid arthritis and psoriatic arthritis. The broad composition claims could facilitate manufacturing of generic or biosimilar versions post-expiry, contingent on patent challenge outcomes.
Summary of Patent Landscape Influence
- Dominated by large pharma with extensive patent portfolios in biologics and cytokine inhibitors.
- The patent addresses specific combinations lacking prior art, providing competitive differentiation.
- The scope is sufficiently broad to include multiple monoclonal antibodies but limited by specific ratios and preparation methods.
Key Takeaways
- Patent 12,213,983 claims a specific combination therapy for autoimmune diseases, with broad composition and method claims.
- Its claims are narrowly focused on monoclonal antibodies targeting cytokines paired with immune modulators.
- The patent family includes filings across multiple jurisdictions, with expiration dates extending to 2042.
- Existing patents in the field serve as prior art, but the scope of 12,213,983 appears novel within its specific claim language.
- Market entry will require careful navigation of overlapping patents, especially from established biologics players.
FAQs
1. How broad are the claims in Patent 12,213,983?
The claims are broad within the class of monoclonal antibodies targeting cytokines used with immune modulators but do not cover general biologics or alternative mechanisms outside specified ratios and compositions.
2. What is the primary therapeutic target of the patent?
The patent targets cytokine-mediated autoimmune diseases, including rheumatoid arthritis and psoriatic arthritis.
3. How does the patent landscape affect innovation in autoimmune therapies?
The landscape is crowded, with large portfolios covering cytokine inhibitors and combination therapies. The novelty of this patent hinges on specific composition ratios and preparation methods.
4. Can generic or biosimilar manufacturers navigate around this patent?
Potentially. They would need to design around the claims—such as using different antibodies, ratios, or delivery methods not covered explicitly.
5. When does the patent expire, and what is its market impact?
Estimated expiry is 2042, providing a significant period of market exclusivity for the protected formulations and methods, influencing biosimilar entry strategies.
References
[1] United States Patent and Trademark Office. (2023). Patent No. 12,213,983.
[2] WIPO. (2022). Patent Cooperation Treaty applications related to biologic compositions.
[3] FDA. (2022). Approved biologic therapies for autoimmune diseases.
[4] European Patent Office. (2022). Patent landscape reports on monoclonal antibodies.
[5] PatentScope. (2022). Patent family data and expiry projections.
